Novo Nordisk buys rights to Emisphere technology for oral insulin for $57.5 million; enters deal with Merrion Pharma

22 December 2010

In a deal that will cost it $57.5 million, Danish insulin giant Novo Nordisk (NYSE: NVO) has entered into an exclusive agreement to develop and commercialize oral formulations of its insulins, which have the potential of treating diabetes, using USA-based Emisphere’s (OTC BB: EMIS) Eligen technology. It also entered into a technology accord with Ireland’s Merrion Pharmaceuticals.

This is the second licence agreement between the two companies. The first was for the development of oral formulations of GLP-1 receptor agonists, which was signed in June 2008 with a potential drug currently in a Phase I clinical trial and worth a potential $87 million to the US firm.

The insulin new accord includes $57.5 million in potential product development and sales milestone payments to Emisphere, of which $5 million will be payable upon signing, as well as royalties on sales. Further financial details of the agreement were not disclosed.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK